Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey Langer

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Practical Radiation Oncology|May 10, 2015
Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guidelineGeorge Rodrigues, Hak Choy, Jeffrey Bradley, et al.
Practical Radiation Oncology|May 10, 2015
Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guidelineGeorge Rodrigues, Hak Choy, Jeffrey Bradley, et al.
JTO Clinical and Research Reports|August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLCOmar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesotheliomaDaniel E Schwed Lustgarten, Charuhas Deshpande, Charu Aggarwal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2016
Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung CancerHann-Hsiang Chao, Abigail T Berman, Charles B Simone, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 16, 2005
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patientsRobert A Schnoll, Randi L Rothman, Dustin B Wielt, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2020
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)Corinne Faivre-Finn, David R Spigel, Suresh Senan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinibAdam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
The Oncologist|July 13, 2024
Calls to action on lung cancer management and researchMay-Lucie Meyer, Fred R Hirsch, Paul A Bunn, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Practical Radiation Oncology|May 10, 2015
Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guidelineGeorge Rodrigues, Hak Choy, Jeffrey Bradley, et al.
Practical Radiation Oncology|May 10, 2015
Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guidelineGeorge Rodrigues, Hak Choy, Jeffrey Bradley, et al.
JTO Clinical and Research Reports|August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLCOmar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesotheliomaDaniel E Schwed Lustgarten, Charuhas Deshpande, Charu Aggarwal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2016
Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung CancerHann-Hsiang Chao, Abigail T Berman, Charles B Simone, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 16, 2005
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patientsRobert A Schnoll, Randi L Rothman, Dustin B Wielt, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2020
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)Corinne Faivre-Finn, David R Spigel, Suresh Senan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinibAdam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
The Oncologist|July 13, 2024
Calls to action on lung cancer management and researchMay-Lucie Meyer, Fred R Hirsch, Paul A Bunn, et al.
Pageof 11